logo
Share SHARE
FONT-SIZE Plus   Neg

Genentech's Obinutuzumab Gets Priority Review For Chronic Lymphocytic Leukemia

The U.S. Food and Drug Administration or FDA has accepted Genentech's Biologics License Application or BLA for obinutuzumab or GA101 and granted Priority Review in the treatment of chronic lymphocytic leukemia or CLL, one of the most common forms of blood cancer, based on final Stage 1 data from the pivotal CLL11 study. This acceptance follows the GA101 FDA Breakthrough Therapy Designation, received in May 2013. The FDA confirmed that the action date is December 20, 2013.

The FDA is assessing data from the pivotal Phase III CLL11 study, which found that GA101 showed a statistically significant 86 percent reduction in the risk of disease worsening or death when combined with chlorambucil chemotherapy compared to chlorambucil alone in previously untreated people with CLL and co-existing medical conditions. In CLL11, no new safety signals were detected for GA101.

GA101, an investigational medicine designed to attack cells that have a certain marker on their surface, is currently being investigated in a large clinical program, including multiple head-to-head Phase III trials versus rituximab in indolent non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. CLL is one of the most common forms of blood cancer and in 2013, it is anticipated that there would be about 5,000 deaths from CLL in the U.S.

Genentech, a member of the Roche Group (RHHBY.PK), has headquarters in South San Francisco, California.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Activist investor Rudolf Bohli is reportedly targeting Switzerland's second largest bank Credit Suisse. Bloomberg reported that Bohli has 0.2 percent stake in Credit Suisse that comes around 100 million francs or around $102 million. Australia's flag carrier Qantas Airways Ltd. on Tuesday took delivery of its first Boeing 787-9 Dreamliner aircraft, noting that the game-changing aircraft will open up new routes and new levels of comfort for travelers. The new aircraft will enable Qantas to operate Australia's first regular non-stop flights to Europe. Flight 666 for HEL departed just after the 13th hour on Friday, October 13, for one last time. Nevertheless, the FinnAir A320 flight from Copenhagen, Denmark, did land safely at HEL - the International Air Transport Association code for Helsinki in Finland - an hour and a half later in partly sunny weather. Friday the 13th is considered an unlucky day in Western superstition.
comments powered by Disqus
Follow RTT